ライフサイエンスコーパス: supraventricular tachycardia

1 low-up (1 to 7 years) of patients with fetal supraventricular tachycardia.

2 outside a health-care setting for paroxysmal supraventricular tachycardia.

3 drug for an episode of perceived paroxysmal supraventricular tachycardia.

4 r ablation with 2 previously misdiagnosed as supraventricular tachycardia.

5 ew consistent associations were observed for supraventricular tachycardia.

6 lation, complete AV block, heart failure and supraventricular tachycardia.

7 ablation of atrioventricular nodal reentrant supraventricular tachycardia.

8 tions, and shocks for atrial fibrillation or supraventricular tachycardia.

9 expensive treatment option for many forms of supraventricular tachycardia.

10 iofrequency ablation to treat other types of supraventricular tachycardia.

11 e while receiving long-term drug therapy for supraventricular tachycardia.

12 l tachycardia from other forms of paroxysmal supraventricular tachycardia.

13 s uncommon, occurring in 1% of patients with supraventricular tachycardia.

14 ymptom (42.2%), followed by heart murmur and supraventricular tachycardia.

15 pathy (DCM), cardiac conduction disease, and supraventricular tachycardias.

16 ats (166 [5.3%] versus 265 [8.3%]; P<0.001), supraventricular tachycardia (1413 [44.7%] versus 1752 [

17 entricular fibrillation (62%), AF (23%), and supraventricular tachycardia (15%).

18 0 consecutive patients presenting with fetal supraventricular tachycardia (17 managed prenatally, 13

19 ions converted 14 of 15 (93%) with reentrant supraventricular tachycardia, 2 of 2 with ventricular or

20 cases that involve (1) differentiation from supraventricular tachycardia; (2) assessment for atypica

21 versus 0.86 [95% CI, 0.28-1.75]; P=0.07) and supraventricular tachycardia (20 [95% CI, 12-31] versus

22 r for inappropriate shock (44%), followed by supraventricular tachycardia (36%), and then abnormal se

23 469; p < .0001) among initial rhythms, i.e., supraventricular tachycardia (60.7%), ventricular tachyc

24 In patients with supraventricular tachycardia, a modified Valsalva manoeu

25 radiofrequency ablation of various forms of supraventricular tachycardia after Mustard and Senning o

26 of primary adverse events for patients with supraventricular tachycardia and ventricular tachycardia

27 2%) of 81 (95% confidence interval, 0.3%-9%) supraventricular tachycardia and ventricular tachycardia

28 lp the operator make the distinction between supraventricular tachycardias and these other forms of v

29 tained monomorphic VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing episodes.

30 requent arrhythmia experienced in childhood, supraventricular tachycardia, and its variants.

31 Most participants had ventricular ectopy, supraventricular tachycardia, and supraventricular ectop

32 Most cases of supraventricular tachycardia are not life-threatening; t

33 Supraventricular tachycardias are less common and are us

34 The low incidence of SCD and low risk of supraventricular tachycardia argue against routine invas

35 e the electrophysiologic mechanisms of fetal supraventricular tachycardia at presentation and postnat

36 an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare

37 bstantial data support a heritable basis for supraventricular tachycardias, but the genetic determina

38 Fetal supraventricular tachycardia causes significant fetal an

39 had higher F1 scores for all classes except supraventricular tachycardia (CNN F1 score, 0.696 vs MUS

40 No supraventricular tachycardias converted to VT or ventric

41 y decreased the risk of atrial fibrillation, supraventricular tachycardia, deep vein thrombosis, resp

42 ithm; ventricular tachycardia/diagnosis; and supraventricular tachycardia/diagnosis.

43 thms with rates of 182 to 250 beats/min, and supraventricular tachycardia discriminators were used fo

44 proved highly effective for the treatment of supraventricular tachycardia during childhood and adoles

45 ardia, sustained ventricular tachycardia, or supraventricular tachycardia during dobutamine infusion

46 One patient developed supraventricular tachycardia during pregnancy and had co

47 One patient developed supraventricular tachycardia during the additional 2 min

48 We randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillat

49 Sustained supraventricular tachycardia (> 12 h) and lower gestatio

50 llation with rapid ventricular response; (6) supraventricular tachycardia (>15 beats).

51 (HR, 0.97; 95% CI, 0.96-0.98; P < .001) and supraventricular tachycardia (HR, 0.96; 95% CI, 0.94-0.9

52 er first shocks due to sinus tachycardia and supraventricular tachycardia (HR: 0.97, p = 0.86) and no

53 01) and increases in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35 to

54 hree requiring hospital admission (sustained supraventricular tachycardia, hypotension, suspected myo

55 Adenosine, the standard therapy for treating supraventricular tachycardia in children and adults with

56 pic tachycardia is a common cause of chronic supraventricular tachycardia in children and can be resi

57 al tachycardia (FAT) is an uncommon cause of supraventricular tachycardia in children.

58 Supraventricular tachycardia in infants can be refractor

59 lysis was to define the incidence of SCD and supraventricular tachycardia in patients with asymptomat

60 tachycardia was the predominant mechanism of supraventricular tachycardia in the fetus.

61 patients developed 38 relapses of paroxysmal supraventricular tachycardia in the ICU after initial co

62 rdiovascular complications during pregnancy: supraventricular tachycardia in two, heart failure in tw

63 IAT episodes were most frequently caused by supraventricular tachycardias in the TV-ICD group (n=83/

64 effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of aty

65 The odds of supraventricular tachycardia increased by a factor of 36

66 ory pathway effective refractory periods and supraventricular tachycardia inducibility in recent inva

67 entriculoatrial conduction during paroxysmal supraventricular tachycardia is a useful diagnostic mane

68 hat the mechanism responsible for paroxysmal supraventricular tachycardia is atrial reentry utilizing

69 Supraventricular tachycardia is common after heart trans

70 ry fetal tachycardia, specifically reentrant supraventricular tachycardia, junctional ectopic, or ven

71 though long-term management of most forms of supraventricular tachycardia lies primarily in the realm

72 The fetal supraventricular tachycardia mechanism was 1:1 atriovent

73 The supraventricular tachycardia mechanism was typical slow/

74 analysis and postnatal confirmation of fetal supraventricular tachycardia mechanisms have been limite

75 Supraventricular tachycardia mechanisms were evaluated b

76 n (n = 4), ventricular fibrillation (n = 6), supraventricular tachycardia (n = 1), and polymorphic ve

77 rial flutter (8/102, 8%), atrial tachycardia/supraventricular tachycardia (n=9/102, 9%), premature ve

78 ence can help differentiate various forms of supraventricular tachycardias, namely atrioventricular n

79 Clinical variables associated with SCD were supraventricular tachycardia (odds ratio [OR], 3.5; 95%

80 odds ratio, 4.9 [95% CI, 2.6-7.6]; P<0.001), supraventricular tachycardia (odds ratio, 3.2 [95% CI, 1

81 ia (VT); 3) pre-excitation; and 4) sustained supraventricular tachycardia of any mechanism.

82 tients (25%): fatigue (two), flushing (one), supraventricular tachycardia (one), and two non-drug-rel

83 low-up ranging from 8 to 96 months), regular supraventricular tachycardia or benign atrial fibrillati

84 centages of both VT/VF (22.3% vs. 28.7%) and supraventricular tachycardia or other non-VT/VF event ep

85 vent free, except for an isolated episode of supraventricular tachycardia, over an average 6-year fol

86 related to survival when initial rhythm was supraventricular tachycardia (p = .04), negatively relat

87 Prompted by symptoms of paroxysmal supraventricular tachycardia, patients self-administered

88 care physician must have a keen awareness of supraventricular tachycardia patterns, mechanisms, preci

89 pacing maneuvers in patients with paroxysmal supraventricular tachycardia (PSVT) in the electrophysio

90 logy and clinical significance of paroxysmal supraventricular tachycardia (PSVT) in the general popul

91 Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medic

92 and efficacy during conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

93 with documented but noninducible paroxysmal supraventricular tachycardia (PSVT) who have evidence of

94 Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinical

95 n with AP-affiliated arrhythmias: paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation

96 Paroxysmal supraventricular tachycardia (PSVT), defined as tachyarr

97 Among patients who have monthly episodes of supraventricular tachycardia, radiofrequency ablation wa

98 ythmia classes: atrial fibrillation, general supraventricular tachycardia, sinus bradycardia and sinu

99 erwent 13 studies to successfully ablate all supraventricular tachycardia substrates in eight (73%) p

100 d AVNRT) as important potential effectors of supraventricular tachycardia susceptibility.

101 We reviewed supraventricular tachycardia (SVT) ablation in adult pat

102 Accessory pathways are a common cause of supraventricular tachycardia (SVT) and can lead to sudde

103 regarding recurrence risk among infants with supraventricular tachycardia (SVT) are limited.

104 Supraventricular tachycardia (SVT) causing heart failure

105 management, including catheter ablation, of supraventricular tachycardia (SVT) in a large series of

106 and sotalol for the treatment of refractory supraventricular tachycardia (SVT) in children <1 year o

107 progression of CHF caused by pacing-induced supraventricular tachycardia (SVT) in pigs.

108 Supraventricular tachycardia (SVT) is one of the most co

109 leven additional patients were recruited for supraventricular tachycardia (SVT) mapping, and seven of

110 appropriate shocks caused by misdetection of supraventricular tachycardia (SVT) remains a substantial

111 patients (8 male; age, 30.5+/-8 years) with supraventricular tachycardia (SVT) underwent catheter ab

112 e syndrome, recurrent episodes of paroxysmal supraventricular tachycardia (SVT) were analyzed to dete

113 lar rhythms, and inappropriate therapies for supraventricular tachycardia (SVT) were compared among 5

114 AF), and 30 patients undergoing ablation for supraventricular tachycardia (SVT) were compared with a

115 and 25 with various arrhythmias: 9 reentrant supraventricular tachycardia (SVT), 2 ventricular tachyc

116 00 PVCs, 74 (42%) had couplets, 67 (37%) had supraventricular tachycardia (SVT), and 56 (31%) had non

117 atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among old

118 ced atrial fibrillation (AF)/atrial flutter, supraventricular tachycardia (SVT), or AE.

119 nitiation and termination of reentrant fetal supraventricular tachycardia (SVT), the most common form

120 llation (VF), and 1368 episodes (n=149) were supraventricular tachycardia (SVT).

121 r systole on the hemodynamic response during supraventricular tachycardia (SVT).

122 in adults, it accounts for 13% of pediatric supraventricular tachycardia (SVT).

123 with tachycardia mechanisms in patients with supraventricular tachycardias (SVT).

124 ers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arr

125 ical atrioventricular node-dependent long RP supraventricular tachycardias (SVTs) can be challenging.

126 ould be more pronounced during an episode of supraventricular tachycardia than during normal rhythm.

127 Among the 73 supraventricular tachycardias, the test accurately predi

128 h could empower patients to treat paroxysmal supraventricular tachycardia themselves outside of a hea

129 endpoint of time to conversion of paroxysmal supraventricular tachycardia to sinus rhythm for at leas

130 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 m

131 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm.

132 From the fetus with supraventricular tachycardia to the adolescent with vaso

133 ting of DCM, cardiac conduction disease, and supraventricular tachycardia, together with increased au

134 d diagnostic criteria were used to determine supraventricular tachycardia type.

135 effectively and safely performed for certain supraventricular tachycardia types in addition to intraa

136 ode examination that required application of supraventricular tachycardia, ventricular fibrillation,

137 a, including atrial fibrillation or flutter, supraventricular tachycardia, ventricular tachycardia, p

138 The risk of supraventricular tachycardia was 16 (95% CI, 10-24) even

139 A total of 156 supraventricular tachycardias were reported involving 98

140 total of 69% of patients were cannulated for supraventricular tachycardia with a median rate of 230 b

141 re included in the differential diagnosis of supraventricular tachycardia with aberrancy, and the use

142 ardia (LPF-VT) is frequently misdiagnosed as supraventricular tachycardia with aberrant right bundle

143 rioventricular conduction in 22 patients and supraventricular tachycardia with atrioventricular block

144 There was a high association of supraventricular tachycardia with atrioventricular block

145 In 44 patients with supraventricular tachycardia with no history of AF or ri

146 ast 18 years and had a history of paroxysmal supraventricular tachycardia with sustained, symptomatic

147 more importantly, in the definitive cure of supraventricular tachycardia with the use of catheter ab

148 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia, with diagnosis and timing

149 Three other patients had supraventricular tachycardias, with success in two and n

150 noson appears to terminate AV node-dependent supraventricular tachycardias without hypotension and br